GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harmony Biosciences Holdings Inc (NAS:HRMY) » Definitions » Piotroski F-Score

Harmony Biosciences Holdings (Harmony Biosciences Holdings) Piotroski F-Score : 5 (As of Apr. 30, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Harmony Biosciences Holdings Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Harmony Biosciences Holdings has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Harmony Biosciences Holdings's Piotroski F-Score or its related term are showing as below:

HRMY' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 6   Max: 6
Current: 5

During the past 6 years, the highest Piotroski F-Score of Harmony Biosciences Holdings was 6. The lowest was 5. And the median was 6.


Harmony Biosciences Holdings Piotroski F-Score Historical Data

The historical data trend for Harmony Biosciences Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harmony Biosciences Holdings Piotroski F-Score Chart

Harmony Biosciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial N/A 6.00 6.00 5.00 5.00

Harmony Biosciences Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 5.00 6.00 5.00

Competitive Comparison of Harmony Biosciences Holdings's Piotroski F-Score

For the Biotechnology subindustry, Harmony Biosciences Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harmony Biosciences Holdings's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Harmony Biosciences Holdings's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 29.485 + 34.3 + 38.461 + 26.607 = $128.9 Mil.
Cash Flow from Operations was 42.559 + 37.063 + 63.1 + 76.665 = $219.4 Mil.
Revenue was 119.126 + 134.216 + 160.268 + 168.412 = $582.0 Mil.
Gross Profit was 98.346 + 109.208 + 127.972 + 125.26 = $460.8 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(673.87 + 715.092 + 760.183 + 777.766 + 811.448) / 5 = $747.6718 Mil.
Total Assets at the begining of this year (Dec22) was $673.9 Mil.
Long-Term Debt & Capital Lease Obligation was $178.6 Mil.
Total Current Assets was $451.1 Mil.
Total Current Liabilities was $163.8 Mil.
Net Income was 21.485 + 23.531 + 87.943 + 48.509 = $181.5 Mil.

Revenue was 85.313 + 107.028 + 117.206 + 128.308 = $437.9 Mil.
Gross Profit was 70.597 + 88.107 + 94.247 + 101.423 = $354.4 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(433.443 + 464.005 + 505.034 + 643.464 + 673.87) / 5 = $543.9632 Mil.
Total Assets at the begining of last year (Dec21) was $433.4 Mil.
Long-Term Debt & Capital Lease Obligation was $189.6 Mil.
Total Current Assets was $400.3 Mil.
Total Current Liabilities was $78.9 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Harmony Biosciences Holdings's current Net Income (TTM) was 128.9. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Harmony Biosciences Holdings's current Cash Flow from Operations (TTM) was 219.4. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=128.853/673.87
=0.19121344

ROA (Last Year)=Net Income/Total Assets (Dec21)
=181.468/433.443
=0.41866635

Harmony Biosciences Holdings's return on assets of this year was 0.19121344. Harmony Biosciences Holdings's return on assets of last year was 0.41866635. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Harmony Biosciences Holdings's current Net Income (TTM) was 128.9. Harmony Biosciences Holdings's current Cash Flow from Operations (TTM) was 219.4. ==> 219.4 > 128.9 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=178.566/747.6718
=0.23882939

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=189.647/543.9632
=0.34863939

Harmony Biosciences Holdings's gearing of this year was 0.23882939. Harmony Biosciences Holdings's gearing of last year was 0.34863939. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=451.07/163.781
=2.75410457

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=400.285/78.884
=5.07434968

Harmony Biosciences Holdings's current ratio of this year was 2.75410457. Harmony Biosciences Holdings's current ratio of last year was 5.07434968. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Harmony Biosciences Holdings's number of shares in issue this year was 58.811. Harmony Biosciences Holdings's number of shares in issue last year was 61.624. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=460.786/582.022
=0.7916986

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=354.374/437.855
=0.80934099

Harmony Biosciences Holdings's gross margin of this year was 0.7916986. Harmony Biosciences Holdings's gross margin of last year was 0.80934099. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=582.022/673.87
=0.86370071

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=437.855/433.443
=1.01017896

Harmony Biosciences Holdings's asset turnover of this year was 0.86370071. Harmony Biosciences Holdings's asset turnover of last year was 1.01017896. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+1+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Harmony Biosciences Holdings has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Harmony Biosciences Holdings  (NAS:HRMY) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Harmony Biosciences Holdings Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Harmony Biosciences Holdings's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Harmony Biosciences Holdings (Harmony Biosciences Holdings) Business Description

Traded in Other Exchanges
N/A
Address
630 West Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
Executives
Peter Anastasiou director C/O HARMONY BIOSCIENCES HOLDINGS, INC., 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Jack Nielsen director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Andreas Wicki director C/O HBM BIOVENTURES (CAYMAN) LTD., CENTENNIAL TOWERS,STE.305,2454 W.BAY RD., GRAND CAYMAN E9 E9
Andrew Serafin officer: Chief Business Officer 630 W. GERMANTOWN PIKE, PLYMOUTH MEETING PA 19462
Jeffrey M. Dayno officer: Chief Medical Officer 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Jeffrey Dierks officer: Chief Commercial Officer 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
John C Jacobs director, officer: President, CEO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Linda M Szyper director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Sandip Kapadia officer: Chief Financial Officer 450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
R. Mark Graf director C/O DISCOVER FINANCIAL SERVICES, 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Eric L Motley director 1516 33RD STREET NW, WASHINGTON DC 20007
Valor Equity Partners Iv-a L.p. 10 percent owner 875 NORTH MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Valor Equity Partners Iv-b L.p. 10 percent owner 875 NORTH MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Marshman Fund Trust Ii 10 percent owner 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Valor Equity Capital Iv Llc 10 percent owner 875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611

Harmony Biosciences Holdings (Harmony Biosciences Holdings) Headlines

From GuruFocus